ITI-007

ITI-007 is an investigational atypical antipsychotic which is currently under development by Intra-Cellular Therapies, licensed from Bristol-Myers Squibb, for the treatment of schizophrenia. It is also being developed by Intra-Cellular Therapies for the treatment of bipolar disorder, depression, and sleep and behavioral disturbance in dementia, autism, and other neuropsychiatric disorders. As of September 2015, ITI-007 has passed the first of two phase III clinical trials for schizophrenia.

Pharmacodynamics

Relative to presently-available antipsychotics, ITI-007 possesses a unique and novel mechanism of action. It acts as a 5-HT_2A receptor antagonist (K_i = 0.54 nM), a partial agonist of presynaptic D₂ receptors and an antagonist of postsynaptic D₂ receptors (K_i = 32 nM), and a SERT blocker (K_i = 61 nM). It also possesses affinity for the D₁ receptor (K_i = 52 nM) and weak affinity for the α_1A- and α_1B-adrenergic receptors (K_i = 173 nM at α₁) and D₄ receptor. ITI-007 does not significantly bind to the 5-HT_2B, 5-HT_2C, H₁, or mACh receptors.

ITI

ITI may refer to:

Karla Šitić

Karla Šitić (born 6 May 1992 in Split, Croatia) is a Croatian distance swimmer. At the 2012 Summer Olympics, she competed in the women's 10 km marathon. She eventually finished 12th, with a time of 1:58:54.7, 1 minute 16.5 seconds behind winner Éva Risztov.

References